Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz242/30081927/mdz242.pdf
Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment;Cancer Drug Resistance;2024-09-13
2. HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial;Journal of Clinical Investigation;2024-02-01
3. Brassica‐derived isothiocyanates as anticancer therapeutic agents and their nanodelivery;Phytotherapy Research;2023-10-26
4. A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs;Expert Opinion on Drug Metabolism & Toxicology;2023-07-03
5. Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer;Cancers;2022-12-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3